120287-85-6

  • Product NameCetrorelix acetate
  • Molecular FormulaC70H92ClN17O14
  • Molecular Weight1431.06
  • Purity99%
  • AppearanceWhite powder
Inquiry

Product Details

Quick Details

  • CasNo: 120287-85-6
  • Molecular Formula: C70H92ClN17O14
  • Appearance: White powder
  • Purity: 99%

Buy High Grade High Purity Cetrorelix acetate 120287-85-6 Fast Shipping

  • Molecular Formula:C70H92ClN17O14
  • Molecular Weight:1431.06
  • Appearance/Colour:White powder 
  • Refractive Index:1.667 
  • PKA:9.82±0.15(Predicted) 
  • PSA:495.67000 
  • Density:1.42 g/cm3 
  • LogP:5.93230 

Cetrorelix acetate(Cas 120287-85-6) Usage

Description

Cetrorelix Acetate, also known as SB-75 acetate, is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM. It is utilized in the treatment of female infertility, particularly in controlled ovulation during in-vitro fertilization (IVF) procedures. Cetrorelix is a decapeptidic analog of luteinizing hormone-releasing hormone (LH-RH) with structural modifications at crucial positions. Notably, it bears the designation [Ac-D-Nal1, D-4-CI Phe-2, D-Pal3, D-Cit6, D-Alal0]-GnRH.

Originator

Asta Medica (Germany)

Uses

This drug acts as an extremely potent and long-acting GnRH antagonist, leading to the immediate blockade of gonadotrophins and sex steroid secretion upon administration. Additionally, it exhibits low histamine-releasing potency. Cetrorelix is distinguished as the first LH-RH antagonist approved worldwide. In Phase III clinical trials, female patients receiving Cetrorelix experienced successful controlled ovulation, preventing premature LH-surge. This positions Cetrorelix as a potential first-choice treatment for IVF, offering advantages over current controlled ovarian hyperstimulation protocols.

Brand name

Cetrotide (Serono).

InChI:InChI=1/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54-,55+,56-,57-,58?/m1/s1

120287-85-6 Relevant articles

The effect of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonists.

Haviv,Fitzpatrick,Nichols,Swenson,Mort,Bush,Diaz,Nguyen,Holst,Cybulski,et al.

, p. 928 - 933 (1993)

-

Methods for the production of peptide derivatives

-

Page/Page column 19, (2010/11/25)

The invention relates to methods for the...

120287-85-6 Process route

Ac-D-Nal-D-Cpa-D-Pal-Ser(tBu)-Tyr(tBu)-D-Cit-Leu-Arg(Pbf)-Pro-D-Ala-NH<sub>2</sub>

Ac-D-Nal-D-Cpa-D-Pal-Ser(tBu)-Tyr(tBu)-D-Cit-Leu-Arg(Pbf)-Pro-D-Ala-NH2

cetrorelix
120287-85-6

cetrorelix

Conditions
Conditions Yield
With chlorotriisopropylsilane; ethane-1,2-dithiol; trifluoroacetic acid; at 20 ℃; for 2h;
 
1-(tert-butoxycarbonyl)-L-proline
15761-39-4,59433-50-0

1-(tert-butoxycarbonyl)-L-proline

<i>N</i>-<i>tert</i>-butoxycarbonyl-<i>L</i>-leucine
13139-15-6,53296-34-7

N-tert-butoxycarbonyl-L-leucine

Boc-(R)-Ala
3744-87-4,7764-95-6,15761-38-3

Boc-(R)-Ala

Boc-Arg(Tos)-OH
13836-37-8

Boc-Arg(Tos)-OH

cetrorelix
120287-85-6

cetrorelix

Conditions
Conditions Yield
Multistep reaction;
 

120287-85-6 Upstream products

  • 15761-39-4
    15761-39-4

    1-(tert-butoxycarbonyl)-L-proline

  • 13139-15-6
    13139-15-6

    N-tert-butoxycarbonyl-L-leucine

  • 3744-87-4
    3744-87-4

    Boc-(R)-Ala

  • 13836-37-8
    13836-37-8

    Boc-Arg(Tos)-OH

Relevant Products